Second-generation BTK inhibitors, such as acalabrutinib and zanubrutinib, have been approved by the EMA and the FDA as monotherapies or in combination with other agents for the treatment of newly diagnosed CLL or SLL and the treatment of patients with relapsed or refractory MCL [96]. Here, BTK is linked to mantle cell lymphoma.